GenMark Diagnostics is a provider of automated, multiplex molecular diagnostic testing systems. The Company develops and commercializes multiplex molecular tests based on its eSensor electrochemical detection technology. It offers four Food and Drug Administration -cleared diagnostic tests which run on its XT-8 instrument; its Respiratory Viral Panel; its Cystic Fibrosis Genotyping Test; its Warfarin Sensitivity Test, and its Thrombophilia Risk Test. GenMark also offers a Hepatitis C genotyping test and associated custom manufactured reagents, as well as a 2C19 Genotyping Test, versions of which are available for use with its XT-8 instrument for research use only.
Type | Public | |
Founded | 2010 | |
HQ | Carlsbad, CA, US | Map |
Website | genmarkdx.com | |
Employee Ratings | ||
Overall Culture | B | More |
USD | |
---|---|
Revenue (FY, 2020) | 171.6m |
Gross profit (FY, 2020) | 67.9m |
Gross profit margin (FY, 2020), % | 39.6% |
Net income (FY, 2020) | (18.6m) |
EBIT (FY, 2020) | (11.1m) |
Market capitalization (26-Apr-2021) | 1.8b |
Closing stock price (26-Apr-2021) | 24.0 |
Cash (31-Dec-2020) | 40.6m |
EV | 1.8b |
USD | Q2, 2011 | Q3, 2011 | Q1, 2012 | Q2, 2012 | Q3, 2012 | Q1, 2013 | Q2, 2013 | Q3, 2013 | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q2, 2018 | Q3, 2018 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 901.0k | 1.3m | 2.2m | 3.6m | 5.3m | 11.1m | 5.2m | 4.6m | 7.9m | 6.6m | 6.3m | 10.1m | 7.6m | 8.5m | 11.1m | 12.5m | 10.8m | 12.5b | 12.4m | 11.6m | 14.9m | 15.8m | 18.4m | 20.9m | 38.7m | 40.1m |
Cost of goods sold | 1.3m | 1.8m | 1.7m | 2.2m | 3.0m | 5.0m | 3.2m | 4.1m | 3.7m | 3.2m | 2.7m | 4.0m | 3.3m | 3.4m | 4.4m | 4.7m | 4.4m | 6.4b | 7.5m | 7.4m | 10.5m | 10.2m | 11.8m | 13.9m | 22.6m | 24.2m |
Gross profit | (393.0k) | (469.0k) | 472.0k | 1.4m | 2.2m | 6.1m | 2.0m | 499.0k | 4.2m | 3.4m | 3.6m | 6.1m | 4.4m | 5.1m | 6.7m | 7.8m | 6.5m | 6.2b | 4.9m | 4.2m | 4.4m | 5.6m | 6.6m | 7.1m | 16.2m | 15.9m |
Gross profit Margin, % | (44%) | (36%) | 22% | 40% | 42% | 55% | 39% | 11% | 53% | 51% | 57% | 61% | 57% | 60% | 60% | 62% | 60% | 49% | 40% | 36% | 30% | 36% | 36% | 34% | 42% | 40% |
USD | Y, 2009 | Y, 2010 | Y, 2011 | FY, 2011 | Y, 2012 | FY, 2012 | Y, 2013 | FY, 2013 | Y, 2014 | FY, 2014 | FY, 2015 | Y, 2015 | FY, 2016 | FY, 2017 | FY, 2019 | FY, 2020 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cash | 16.5m | 51.3m | 25.3m | 25.3m | 51.3m | 51.3m | 35.7m | 35.7m | 36.9m | 36.9m | 35.4m | 35.4m | 16.0m | 26.8m | 44.4m | 40.6m |
Accounts Receivable | 1.1m | 3.2m | 2.9m | 4.9m | 6.8m | 10.7m | 16.8m | 20.8m | ||||||||
Prepaid Expenses | 322.0k | 226.0k | 552.0k | 575.0k | 591.0k | 1.8m | 1.9m | 2.7m | ||||||||
Inventories | 2.2m | 2.0m | 2.1m | 2.1m | 2.1m | 2.1m | 3.1m | 3.1m | 3.1m | 10.9m | 11.3m | 21.3m |
USD | Q2, 2011 | Q3, 2011 | Q1, 2012 | Q2, 2012 | Q3, 2012 | Q1, 2013 | Q2, 2013 | Q3, 2013 | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q2, 2018 | Q3, 2018 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cash | 43.5m | 31.0m | 23.8m | 64.2m | 53.4m | 32.0m | 18.8m | 63.3m | 27.9m | 26.8m | 25.7m | 36.9m | 32.1m | 34.2m | 27.9m | 29.6m | 19.3m | 13.2m | 88.4m | 27.2m | 28.9m | 25.0m | 23.7m | 24.3m | 26.3m | 82.4m | 57.8m |
Accounts Receivable | 640.0k | 724.0k | 1.1m | 1.3m | 1.2m | 4.4m | 4.4m | 2.4m | 2.6m | 2.1m | 2.7m | 4.4m | 4.3m | 5.4m | 5.4m | 5.1m | 7.3m | 7.8m | 7.1m | 9.9m | 6.8m | 10.4m | 25.7m | 17.9m | 16.2m | ||
Prepaid Expenses | 495.0k | 428.0k | 135.0k | 192.0k | 183.0k | 382.0k | 772.0k | 682.0k | 627.0k | 1.1m | 1.2m | 770.0k | 874.0k | 623.0k | 1.3m | 1.2m | 1.3m | 2.0m | 1.9m | 1.9m | 2.1m | 2.1m | 1.8m | 1.8m | 2.8m | ||
Inventories | 1.2m | 2.0m | 2.1m | 1.9m | 2.1m | 3.2m | 3.4m | 2.0m | 1.8m | 1.2m | 1.5m | 2.1m | 2.0m | 2.7m | 2.4m | 2.6m | 4.2m | 9.0m | 7.1m | 7.1m | 8.8m | 11.3m | 9.9m | 12.6m | 9.9m | 14.9m | 19.6m |
USD | FY, 2011 | FY, 2012 | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2019 | FY, 2020 |
---|---|---|---|---|---|---|---|---|---|
Net Income | (24.0m) | (22.1m) | (33.6m) | (38.3m) | (42.2m) | (50.6m) | (61.8m) | (47.3m) | (18.6m) |
Depreciation and Amortization | 1.3m | 1.2m | 2.5m | 2.7m | 3.4m | 3.9m | 5.3m | 7.3m | 7.1m |
Inventories | (1.7m) | (880.0k) | (1.3m) | (229.0k) | (1.3m) | (3.4m) | (10.5m) | (6.5m) | (12.5m) |
Accounts Payable | 378.0k | 728.0k | 1.3m | 85.0k | (757.0k) | 4.1m | 2.6m | 1.5m | 5.2m |
USD | Q2, 2011 | Q3, 2011 | Q1, 2012 | Q2, 2012 | Q3, 2012 | Q1, 2013 | Q2, 2013 | Q3, 2013 | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q2, 2017 | Q3, 2017 | Q2, 2018 | Q3, 2018 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Income | (12.2m) | (18.5m) | (5.6m) | (11.2m) | (17.4m) | (4.2m) | (12.2m) | (23.0m) | (8.8m) | (20.0m) | (29.7m) | (9.9m) | (33.4m) | (13.0m) | (25.9m) | (37.9m) | (25.4m) | (37.1m) | (7.0m) | ||||||
Depreciation and Amortization | 622.0k | 948.0k | 264.0k | 576.0k | 918.0k | 498.0k | 1.0m | 1.9m | 574.0k | 1.2m | 1.9m | 797.0k | 2.7m | 900.0k | 1.8m | 2.7m | 2.5m | 3.8m | 3.5m | 5.3m | 3.6m | 5.4m | 1.8m | 3.5m | 5.4m |
Inventories | (275.0k) | (1.4m) | 757.0k | 1.1m | (402.0k) | (1.5m) | (1.8m) | (216.0k) | 169.0k | 608.0k | 209.0k | (366.0k) | (980.0k) | 501.0k | 306.0k | 1.0m | (2.6m) | (4.8m) | (353.0k) | (3.8m) | (1.4m) | (5.5m) | 920.0k | (5.0m) | (10.2m) |
Accounts Payable | 1.4m | 510.0k | (112.0k) | 369.0k | 907.0k | 129.0k | (310.0k) | 570.0k | (449.0k) | (501.0k) | (318.0k) | (775.0k) | (358.0k) | 617.0k | 1.3m | 916.0k | (3.1m) | (1.5m) | (1.9m) | (3.4m) | (1.1m) | 345.0k | (1.6m) | 3.6m | 7.4m |
FY, 2014 | FY, 2015 | FY, 2016 | |
---|---|---|---|
Patents Issued | 130 | 120 | 100 |
Patents Pending | 25 | 35 | 30 |
B
74/100
C-
64/100
B
74/100
When was GenMark Diagnostics founded?
GenMark Diagnostics was founded in 2010.
Who are GenMark Diagnostics key executives?
GenMark Diagnostics's key executives are Tanya Monga, Wade Stevenson and Tracy Clements.
How many employees does GenMark Diagnostics have?
GenMark Diagnostics has 437 employees.
What is GenMark Diagnostics revenue?
Latest GenMark Diagnostics annual revenue is $171.6 m.
What is GenMark Diagnostics revenue per employee?
Latest GenMark Diagnostics revenue per employee is $392.6 k.
Who are GenMark Diagnostics competitors?
Competitors of GenMark Diagnostics include Nelson Labs, IsoPlexis and Cue.
Where is GenMark Diagnostics headquarters?
GenMark Diagnostics headquarters is located at 5964 La Place Ct, Carlsbad.
Where are GenMark Diagnostics offices?
GenMark Diagnostics has offices in Carlsbad, Albany, Atlanta, Birmingham and in 29 other locations.
How many offices does GenMark Diagnostics have?
GenMark Diagnostics has 33 offices.
Receive alerts for 300+ data fields across thousands of companies